138 reports of this reaction
1.3% of all BUROSUMAB reports
#20 most reported adverse reaction
INJECTION SITE ERYTHEMA is the #20 most commonly reported adverse reaction for BUROSUMAB, manufactured by Kyowa Kirin, Inc.. There are 138 FDA adverse event reports linking BUROSUMAB to INJECTION SITE ERYTHEMA. This represents approximately 1.3% of all 10,519 adverse event reports for this drug.
Patients taking BUROSUMAB who experience injection site erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE ERYTHEMA is a less commonly reported adverse event for BUROSUMAB, but still significant enough to appear in the safety profile.
In addition to injection site erythema, the following adverse reactions have been reported for BUROSUMAB:
The following drugs have also been linked to injection site erythema in FDA adverse event reports:
INJECTION SITE ERYTHEMA has been reported as an adverse event in 138 FDA reports for BUROSUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE ERYTHEMA accounts for approximately 1.3% of all adverse event reports for BUROSUMAB, making it a notable side effect.
If you experience injection site erythema while taking BUROSUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.